{"entity":{"id":"spevatamig","kind":"drug","name":"Spevatamig","aka":["Spevatamig (PT886)"],"tldr":"Spevatamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, aimed at Claudin 18.2 and CD47.","summary":"Spevatamig (PT886) is a bispecific antibody developed by Phanes Therapeutics. Its targets are Claudin 18.2 and CD47. ClinicalTrials.gov describes the intervention as: Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer. The largest, NCT05482893, plans to enrol 258 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Spevatamig","url":"https://clinicaltrials.gov/search?intr=PT886"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","pancreatic","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":["cldn18-2","cd47"],"drugs":[],"companies":["phanes-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05482893"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"PT886","modality":"bispecific antibody","mechanism":"Bispecific antibody directed at Claudin 18.2 and CD47, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/spevatamig/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/"},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"phanes-therapeutics","kind":"company","name":"Phanes Therapeutics","route":"/companies/phanes-therapeutics/"}],"trial":[{"id":"nct05482893","kind":"trial","name":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct","route":"/trials/nct05482893/"}]}}